IPP ANALYTICS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +14.7%

  £20,278,000 → £23,261,000

• Cash

  —

  Not reported

• Net assets

  +4.2%

  -£23,629,000 → -£22,634,000

• Employees

  +1.7%

  421 → 428

• Operating profit

  +3,954.5%

  £55,000 → £2,230,000

• Profit before tax

  +184.2%

  -£1,147,000 → £966,000

• Wages

  +3.9%

  £14,966,000 → £15,546,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors consider the going concern basis to be appropriate following their assessment of the Company's financial position and its ability to meet its obligations as and when they fall due. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.”

Group structure

1. IPP ANALYTICS LIMITED · parent
   1. Pathology First LLP 49% · UK · pathology services

Significant events

• “Revenue for the year was 14.7% higher than prior year and was mainly due to improved terms of a contract extension with the Company's main customer, Mid and South Essex NHS Foundation Trust. Test volumes were modestly improved from prior year with an increase of 1.3%. The contract extension commenced in October 2024 and expires in September 2026. Following the expiry of the extension, a fifteen year contract will commence which has already been signed by the involved parties.”
• “Finance costs have decreased by 12.2% mainly due to decrease in the interest rate charged by Labco UK Group Limited and partly due to a reduction in the Company's internal debt.”
• “The Company will continue to provide analytical services under an extended contract. which ends on 30 September 2026. In October 2026, the Company will commence delivery of services for a 15-year contract with the Mid and South Essex NHS Foundation Trust. This agreement establishes a unified pathology service supporting GP practices and clinicians across Basildon, Broomfield, and Southend hospitals, serving a combined patient population of approximately 1.2 million.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.